Literature DB >> 18448624

Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable.

Xuelian Wang1, Anna-Barbara Moscicki, Laura Tsang, Andrea Brockman, Mayumi Nakagawa.   

Abstract

Human papillomavirus (HPV)-specific T-cell response to the HPV type 16 (HPV16) E6 protein has been shown to be associated with successful viral clearance. The patterns of CD8 T-cell epitopes within HPV16 E6 protein were previously studied in two women with HPV16 clearance. The goal of this study was to characterize these epitopes in terms of their minimal and optimal amino acid sequences and the human leukocyte antigen (HLA) restriction molecules. The presence of the epitope-specific memory T cells after viral clearance was also examined. In subject A, the dominant epitope was characterized to be E6 75-83 (KFYSKISEY), restricted by the HLA-B62 molecule, while that of subject B was E6 133-142 (HNIRGRWTGR), restricted by the HLA-A6801 molecule. Homologous epitopes were identified in five other high-risk HPV types for both of these epitopes, but they were not recognized by respective T-cell clone cells. An enzyme-linked immunospot assay or tetramer analysis was performed on peripheral blood mononuclear cells from blood samples collected after viral clearance but prior to isolation of the T-cell clones. The presence of epitope-specific memory T cells was demonstrated. These data suggest that HPV-specific memory T cells were generated in vivo and that they may remain in circulation many months, if not years, after viral clearance. Our findings broaden the spectrum of the CD8 T-cell epitopes of the HPV16 E6 protein. The characterization of novel T-cell epitopes and long-lasting epitope-specific memory T cells may be useful for the development of a potential epitope-based vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18448624      PMCID: PMC2446617          DOI: 10.1128/CVI.00404-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  31 in total

Review 1.  Effector and memory T-cell differentiation: implications for vaccine development.

Authors:  Susan M Kaech; E John Wherry; Raft Ahmed
Journal:  Nat Rev Immunol       Date:  2002-04       Impact factor: 53.106

2.  A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

Authors:  L Muderspach; S Wilczynski; L Roman; L Bade; J Felix; L A Small; W M Kast; G Fascio; V Marty; J Weber
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

3.  Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

Authors:  M E Ressing; W J van Driel; R M Brandt; G G Kenter; J H de Jong; T Bauknecht; G J Fleuren; P Hoogerhout; R Offringa; A Sette; E Celis; H Grey; B J Trimbos; W M Kast; C J Melief
Journal:  J Immunother       Date:  2000 Mar-Apr       Impact factor: 4.456

4.  Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.

Authors:  S J Youde; P R Dunbar; E M Evans; A N Fiander; L K Borysiewicz; V Cerundolo; S Man
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

5.  Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens.

Authors:  M Nakagawa; D P Stites; S Patel; S Farhat; M Scott; N K Hills; J M Palefsky; A B Moscicki
Journal:  J Infect Dis       Date:  2000-07-28       Impact factor: 5.226

6.  Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif.

Authors:  I Bourgault Villada; N Bénéton; C Bony; F Connan; J Monsonego; A Bianchi; P Saiag; J P Lévy; J G Guillet; J Choppin
Journal:  Eur J Immunol       Date:  2000-08       Impact factor: 5.532

7.  Evolution of epitope-specific memory CD4(+) T cells after clearance of hepatitis C virus.

Authors:  Andrew J Godkin; Howard C Thomas; Peter J Openshaw
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

8.  Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins.

Authors:  Mayumi Nakagawa; Kevin H Kim; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

9.  ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial.

Authors:  Francisco Garcia; Karl Ulrich Petry; Laila Muderspach; Michael A Gold; Patricia Braly; Christopher P Crum; Marianne Magill; Michael Silverman; Robert G Urban; Mary Lynne Hedley; Kathleen J Beach
Journal:  Obstet Gynecol       Date:  2004-02       Impact factor: 7.661

10.  Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.

Authors:  Ingeborg Zehbe; Andreas M Kaufmann; Markus Schmidt; Hanni Hohn; Markus J Maeurer
Journal:  J Immunother       Date:  2007 Jul-Aug       Impact factor: 4.456

View more
  11 in total

1.  Association between toll-like receptor expression and human papillomavirus type 16 persistence.

Authors:  Ibrahim I Daud; Mark E Scott; Yifei Ma; Stephen Shiboski; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

2.  Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.

Authors:  Carlos A Ramos; Neeharika Narala; Gayatri M Vyas; Ann M Leen; Ulrike Gerdemann; Erich M Sturgis; Matthew L Anderson; Barbara Savoldo; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

3.  Use of interferon-γ enzyme-linked immunospot assay to characterize novel T-cell epitopes of human papillomavirus.

Authors:  Xuelian Wang; William W Greenfield; Hannah N Coleman; Lindsey E James; Mayumi Nakagawa
Journal:  J Vis Exp       Date:  2012-03-08       Impact factor: 1.355

4.  A Human Papillomavirus Type 16 E6 52-62 CD4 T-Cell Epitope Restricted by the HLA-DR11 Molecule Described in an Epitope Hotspot.

Authors:  Hannah N Coleman; Xuelian Wang; William W Greenfield; Mayumi Nakagawa
Journal:  MOJ Immunol       Date:  2014

5.  CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.

Authors:  Samantha Seresini; Massimo Origoni; Luigi Caputo; Flavia Lillo; Renato Longhi; Simone Vantini; Anna Maria Paganoni; Maria Pia Protti
Journal:  Immunology       Date:  2010-06-02       Impact factor: 7.397

Review 6.  Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines.

Authors:  Mayumi Nakagawa; William Greenfield; Andrea Moerman-Herzog; Hannah N Coleman
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

7.  Biomarkers of oxidant load and type-specific clearance of prevalent oncogenic human papillomavirus infection: markers of immune response?

Authors:  Erin M Siegel; Nitin Patel; Beibei Lu; Ji-Hyun Lee; Alan G Nyitray; Neal E Craft; Krystyna Frenkel; Luisa L Villa; Eduardo L Franco; Anna R Giuliano
Journal:  Int J Cancer       Date:  2011-11-28       Impact factor: 7.396

8.  Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.

Authors:  I Bourgault Villada; M Moyal Barracco; S Berville; M L Bafounta; C Longvert; V Prémel; P Villefroy; E Jullian; T Clerici; B Paniel; B Maillère; J Choppin; J G Guillet
Journal:  Clin Exp Immunol       Date:  2009-07-30       Impact factor: 4.330

9.  A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.

Authors:  William W Greenfield; Shawna L Stratton; Rebecca S Myrick; Rita Vaughn; Lisa M Donnalley; Hannah N Coleman; Maria Mercado; Andrea M Moerman-Herzog; Horace J Spencer; Nancy R Andrews-Collins; Wilbur C Hitt; Gordon M Low; Nirvana A Manning; Samantha S McKelvey; Dora Smith; Michael V Smith; Amy M Phillips; C Matthew Quick; Susanne K Jeffus; Laura F Hutchins; Mayumi Nakagawa
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

10.  A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant.

Authors:  Al-Ola Abdallah; Hannah Coleman; Mohamed Kamel; Rodney Davis; Teri Landrum; Horace Spencer; Sam Mackintosh; Fade A Mahmoud; Natasa Milojkovic; Chester Wicker; Konstantinos Arnaoutakis; Mayumi Nakagawa
Journal:  SAGE Open Med       Date:  2018-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.